HotSpot Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- HotSpot Therapeutics's estimated annual revenue is currently $15.5M per year.
- HotSpot Therapeutics's estimated revenue per employee is $155,000
- HotSpot Therapeutics's total funding is $210M.
Employee Data
- HotSpot Therapeutics has 100 Employees.
- HotSpot Therapeutics grew their employee count by 9% last year.
HotSpot Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Accounting and Corporate Controller | Reveal Email/Phone |
2 | VP, Finance | Reveal Email/Phone |
3 | VP, Development Operations | Reveal Email/Phone |
4 | SVP | Reveal Email/Phone |
5 | VP, Data Science and Platform Biology | Reveal Email/Phone |
6 | VP and Head, Translational Sciences and Clinical Biomarkers | Reveal Email/Phone |
7 | VP, Head Immunology | Reveal Email/Phone |
8 | SVP, Platform Integration Sciences | Reveal Email/Phone |
9 | EVP, Head Chemical Sciences | Reveal Email/Phone |
10 | VP, Biology | Reveal Email/Phone |
HotSpot Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is HotSpot Therapeutics?
Inspired by natureￃﾢ￢ﾂﾬ￢ﾄﾢs ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover natureￃﾢ￢ﾂﾬ￢ﾄﾢs privileged regulatory hotspots ￃﾢ￢ﾂﾬ￢ﾀﾜ pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties. HotSpot is supported by a syndicate of leading healthcare investors based in the US and Europe.
keywords:N/A
$210M
Total Funding
100
Number of Employees
$15.5M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
HotSpot Therapeutics News
... serves as Chief Development Officer at HotSpot Therapeutics, ... the early development portfolio across therapeutic areas in oncology,...
About HotSpot Therapeutics, Inc. HotSpot Therapeutics is targeting naturally occurring pockets on proteins called "natural hotspots" that are...
HotSpot Therapeutics, a Boston, MA-based biotechnology company advancing the discovery and development of first-in-class allosteric therapies targeting nature’s regulatory sites, closed a $65m Series B financing. The round was led by S.R. One, Limited and included funds managed by Tekla Capital ...
HotSpot Therapeutics has raised a $65 million series B to fund development of allosteric medicines. The financing, which was led by GlaxoSmithKline’s SR One, positions HotSpot to move treatments for autoimmune disease and rare metabolic conditions into the clinic. Sponsored by Agilent Technolog ...
HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature's regulatory sites, today announced the completion of a $65 million Series B financing. The financing round was led by S.R. One, Limited and include ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24.3M | 100 | -5% | $52.8M |
#2 | $14M | 100 | -15% | $35.5M |
#3 | $15M | 100 | -21% | N/A |
#4 | $15M | 100 | 16% | N/A |
#5 | $27M | 100 | 1% | N/A |